Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels.
Nicoll AJ, Roberts SK, Lim R, Mitchell J, Weltman M, George J, Wigg A, Stuart K, Gow P, MacQuillan G, Tse E, Levy M, Sood S, Zekry A, Cheng W, Mitchell J, Skoien R, Sievert W, Strasser SI, McCaughan GW; ALA Clinical Research Network, Gastroenterological Society of Australia. Nicoll AJ, et al. Among authors: weltman m. Aliment Pharmacol Ther. 2019 May;49(10):1314-1322. doi: 10.1111/apt.15248. Epub 2019 Apr 11. Aliment Pharmacol Ther. 2019. PMID: 30972807
Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial.
Roberts SK, Weltman MD, Crawford DH, McCaughan GW, Sievert W, Cheng WS, Rawlinson W, Desmond PV, Marks PS, Yoshihara M, Rizkalla B, Depamphilis JK, Dore GJ; Chariot Study Group. Roberts SK, et al. Among authors: weltman md. Hepatology. 2009 Oct;50(4):1045-55. doi: 10.1002/hep.23130. Hepatology. 2009. PMID: 19676125 Clinical Trial.
Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing.
Cheng WS, Roberts SK, McCaughan G, Sievert W, Weltman M, Crawford D, Rawlinson W, Marks PS, Thommes J, Rizkalla B, Yoshihara M, Dore GJ; CHARIOT Study Group. Cheng WS, et al. Among authors: weltman m. J Hepatol. 2010 Oct;53(4):616-23. doi: 10.1016/j.jhep.2010.04.024. Epub 2010 Jun 16. J Hepatol. 2010. PMID: 20619475 Clinical Trial.
Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1.
Sievert W, Dore GJ, McCaughan GW, Yoshihara M, Crawford DH, Cheng W, Weltman M, Rawlinson W, Rizkalla B, Depamphilis JK, Roberts SK; CHARIOT Study Group. Sievert W, et al. Among authors: weltman m. Hepatology. 2011 Apr;53(4):1109-17. doi: 10.1002/hep.24180. Hepatology. 2011. PMID: 21480317 Clinical Trial.
Hepatitis C treatment outcomes in Australian clinics.
Gidding HF, Law MG, Amin J, Ostapowicz G, Weltman M, Macdonald GA, Sasadeusz JJ, Haber PA, George J, Dore GJ. Gidding HF, et al. Among authors: weltman m. Med J Aust. 2012 Jun 4;196(10):633-7. doi: 10.5694/mja12.10014. Med J Aust. 2012. PMID: 22676878 Clinical Trial.
137 results